As per FirstWord, Johnson & Johnson announced plans to consolidate marketing and sales operations of subsidiaries Ortho Biotech and Centocor, in response to declining sales of anaemia drug Procrit amidst safety concerns. The move is expected to result in the elimination of between 400 and 450 jobs by the end of the year.
Kim Taylor, current president of commercial operations for Ortho Biotech, has been selected to head the merged sales and marketing force, which will be located at Centocor’s headquarters in Pennsylvania. The company expects to begin transitioning personnel to the new headquarters in September
No comments:
Post a Comment